Form 4 for ETON Eton Pharmaceuticals, Inc.
Accepted 2026-07-14 17:28:16 ET · period of report 2026-07-12 · accession 0001437749-26-023570 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-07-14 17:28 | 2026-07-12+ | ETON | BRYNJELSEN SEAN | Pres, CEO, Dir | M - OptEx | $1.37 | +227.5K | 1.06M | +27% | +$311.7K |
| DM | 2026-07-14 17:28 | 2026-07-12+ | ETON | BRYNJELSEN SEAN | Pres, CEO, Dir | M - OptEx | $0.00 | +172.5K | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-12 | M | A | 27,500 | — | 861,194 | D | — | — | (F1) On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023. |
| 2 | Common | Common Stock | 2026-07-14 | M | A | 200,000 | $1.37 | 1,061,194 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2026-07-12 | M | D | 27,500 | $0.00 | 0 | D | $0.00 · — to — | 27,500 Common Stock | (F1) On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023. (F1) On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023. |
| 4 | Derivative | Employee Stock Option | 2026-07-14 | M | A | 200,000 | $0.00 | 0 | D | $1.37 · 2017-11-10 to 2027-11-09 | 200,000 Common Stock | (F2) The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments. |